MedTrace Logo

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

NCT02722512 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-02-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable High-Grade Gliomas and Ependymomas.

Conditions

Interventions

BIOLOGICAL

Heat Shock Protein Peptide Complex-96 (HSPPC-96)

The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.

PROCEDURE

Tumor Resection

Clinically-indicated removal of the tumor

RADIATION

Radiation

Focal Radiation Therapy

Sponsors & Collaborators

Principal Investigators

  • Stewart Goldman, MD · Ann and Robert H Lurie Childrens Hospital of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-11-13
Completion
2019-11-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02722512 on ClinicalTrials.gov